Butler, James

Abstract Objective Pediatric epilepsy surgery is well established, but contemporary global data on referral and presurgical evaluation practices are lacking. This International League Against Epilepsy (ILAE) Pediatric Epilepsy Surgery Task Force study provides an updated overview of current trends and regional differences. Methods Group‐level data were collected from 61 epilepsy surgery programs (49 pediatric‐only) across 29 countries and six continents, identified through ILAE networks, and included all children and adolescents treated in 2023 who underwent presurgical evaluation/epilepsy surgery. Results Group‐level data were available for 2427 patients. Mean age at surgery was 9.1 ± 4.9 years; mean epilepsy duration was 5.3. At surgery, 3.2% were <1 year old (highest in Oceania: 5.1%), and 6.1% were nonpharmacoresistant (highest in Europe: 15.0%). Prior neurosurgery was reported in 14.2% (highest in North America: 28.8%), including 8.0% resections (6.1% for epilepsy, 1.5% for tumors; highest in Oceania: 16.5%), 2.3% disconnections (1.3% corpus callosotomy; highest in South America: 4.7%), and 4.2% neuromodulation (3.7% vagal nerve stimulation, .2% responsive neurostimulation, one deep brain stimulation; highest in North America: 12.2%). Developmental and epileptic encephalopathies (DEEs) at surgery included Lennox–Gastaut syndrome (7.4%), infantile epileptic spasms syndrome (5.1%), and DEE with spike–wave activation in sleep (1.5%). Presurgical investigations included fluorodeoxyglucose positron emission tomography (52.6%; highest in Oceania: 79.7%), genetic testing (46.8%; highest in Asia: 54.3%), magnetic resonance imaging (MRI) postprocessing (32.4%; highest in South America: 53.0%), functional MRI (fMRI; 15.2%; highest in North America: 40.3%), magnetoencephalography (11.9%; highest in North America: 39.3%), single photon emission computed tomography (9.6%; highest in North America: 22.2%), high‐density electroencephalography (EEG; 1.9%; highest in Europe: 4.7%), source localization (1.6%; highest in Oceania: 7.6%), Wada test (1.2%; highest in North America: 3.5%), and EEG‐fMRI (.5%; highest in Europe: 1.1%). Significance Despite some early surgeries, including in infancy and before pharmacoresistance, mean epilepsy duration before surgery remains >5 years. Reoperations are common, with resection more frequent than neuromodulation. Genetic testing in nearly half of patients reflects its growing relevance, and the high rate of DEEs underscores the complexity of surgical candidates.

In pathologies of the heart, blood vessels, and airways, and in cancer as well, the ultimate therapeutic target is often modulation of cellular contractile force. For discovering new therapies, drug screening technologies typically use biochemical or structural surrogates for contractile force rather than contractile force itself. Because such approaches are indirect, some hits are false while other potential hits could be missed. To fill this gap, we developed a new high‐throughput method that utilizes cellular contractile force directly as the reporter ‐‐called contractile force screening (CFS)‐‐ and established feasibility of CFS in the context of drug discovery in asthma. During an acute asthma attack, contractile forces generated by airway smooth muscle cells act to constrict the airway and thus obstruct airflow. To dilate constricted airways, asthma patients use bronchodilators to reduce these contractile forces and thus allow the airway to open more fully, but currently available bronchodilator medications often fail to relax that muscle sufficiently, especially in severe asthma. To address this unmet need for more effective bronchodilator medications, we implemented CFS to evaluate 10,000 small molecule compounds selected randomly from the Chembridge DIVERset® library. Acrylamide gels were made in 96‐well plates and fluorescent markers and collagen were coated onto gel surfaces. Upon each gel we cultured primary human airway smooth muscle (HASM) cells to near confluence. Drug effects were quantified as the ‘force response ratio’, namely, the ratio of the contractile forces before and after drug addition. By screening mixtures of 8 compounds simultaneously, we were able to evaluate 2000 compounds per week in quadruplicate. After retesting individual compounds from initially positives, we identified 2 individual compounds that relaxed HASM cells in a dose‐dependent and a non‐toxic manner. The mechanism of action is still under investigation but we found that these compounds work independent of cAMP. CFS provides a convenient, rapid, and inexpensive platform for drug discovery based upon a physiological endpoint, namely, cell contractile force. Furthermore, CFS technology has the potential to become a new high‐content assay for drug discovery in any disease process in which cellular contractile force plays a central role. Support or Funding Information NIH P50HL107171 (CADET phase I), R01EY019696 (Eye BRP), NRF GRN (NRF‐2013S1A2A2035518)